Definium Therapeutics (DFTX) has attracted market attention after dosing the first patient in Ascend, its second Phase 3 trial of DT120 ODT in major depressive disorder, alongside progress across multiple late stage studies.
See our latest analysis for Definium Therapeutics.
Definium’s latest clinical updates come after a strong run in the stock, with a 90 day share price return of 31.35% and a year to date share price return of 64.96%. The 1 year total shareholder return is 208.22% and the 3 year total shareholder return is very large, even though the 5 year total shareholder return declined 55.88%. This points to powerful but relatively recent momentum around DT120, driven by successive Phase 3 milestones and FDA Breakthrough Therapy Designation.
If you are interested in other opportunities around brain health and next generation treatments, it could be worth scanning the wider set of 34 healthcare AI stocks.
With DT120 progressing through multiple Phase 3 trials and Definium still loss making, the sharp share price gains and the wide gap to analyst targets raise a key question: is there still a buying opportunity here, or is the market already pricing in future growth?
Most Popular Narrative: 36.1% Undervalued
At a last close of $22.50 versus a most widely followed fair value estimate of $35.23, the current price sits well below that narrative anchor, and the narrative rests heavily on how DT120 could reshape Definium’s profile if late stage data and regulation line up.
Approaching three pivotal Phase III readouts for DT120 ODT in GAD and MDD in 2026 positions the company to potentially transition from a pure R&D story toward a commercial stage profile, which could materially affect future revenue visibility and earnings power if outcomes support regulatory filings.
Want to see what has to happen between now and those readouts to support that fair value? The narrative leans on rapid revenue build, margin expansion and a premium earnings multiple that is well above the broader pharmaceuticals sector. Curious how those pieces are stitched together and what discount rate is applied to pull it all back to today’s $ price? The full breakdown shows exactly how those assumptions line up against Definium’s current loss making profile.
Result: Fair Value of $35.23 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this upbeat story can flip quickly if DT120’s Phase 3 data disappoints or if ongoing losses and potential equity raises weigh on sentiment around future earnings.
Find out about the key risks to this Definium Therapeutics narrative.
Next Steps
Feeling torn between the optimism around DT120 and the concerns about ongoing losses? Act while the information is fresh, and weigh both sides for yourself through the 2 key rewards and 4 important warning signs.
Looking for more investment ideas?
You do not need to stop with Definium. Use the Simply Wall Street Screener to quickly surface fresh stock ideas that could fit your portfolio and style.
- Target potential value opportunities early by scanning 49 high quality undervalued stocks that some investors may be overlooking right now.
- Prioritise capital preservation with 66 resilient stocks with low risk scores that score well on a broad set of risk checks.
- Get ahead of the crowd by reviewing a screener containing 21 high quality undiscovered gems before they attract wider market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com